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Abstract
Background: According to the prevailing view, soluble oligomers or small fibrillar fragments are considered to be the most
toxic species in prion diseases. To test this hypothesis, two conformationally different amyloid states were produced from
the same highly pure recombinant full-length prion protein (rPrP). The cytotoxic potential of intact fibrils and fibrillar
fragments generated by sonication from these two states was tested using cultured cells.
Methodology/Principal Findings: For one amyloid state, fibril fragmentation was found to enhance its cytotoxic potential,
whereas for another amyloid state formed within the same amino acid sequence, the fragmented fibrils were found to be
substantially less toxic than the intact fibrils. Consistent with the previous studies, the toxic effects were more pronounced
for cell cultures expressing normal isoform of the prion protein (PrP
C) at high levels confirming that cytotoxicity was in part
PrP
C-dependent. Silencing of PrP
C expression by small hairpin RNAs designed to silence expression of human PrP
C (shRNA-
PrP
C) deminished the deleterious effects of the two amyloid states to a different extent, suggesting that the role of PrP
C-
mediated and PrP
C-independent mechanisms depends on the structure of the aggregates.
Conclusions/Significance: This work provides a direct illustration that the relationship between an amyloid’s physical
dimension and its toxic potential is not unidirectional but is controlled by the molecular structure of prion protein (PrP)
molecules within aggregated states. Depending on the structure, a decrease in size of amyloid fibrils can either enhance or
abolish their cytotoxic effect. Regardless of the molecular structure or size of PrP aggregates, silencing of PrP
C expression
can be exploited to reduce their deleterious effects.
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Introduction
Etiology and progression of several neurodegenerative diseases
including Alzheimer’s, Parkinson’s, Huntington’s and prion
diseases are linked to the accumulation of protein aggregates in
the form of large amyloid fibrils/plaques, or small oligomers or
fibrillar fragments [1–4]. According to the prevailing opinion,
oligomers or small fibrillar fragments are the most toxic species
and are responsible for the impairment of cellular functions,
whereas mature fibrils or plaques are considered to be protective
[3–7]. Small soluble oligomers could be produced as prefibrillar
intermediates on the pathway to mature amyloid fibrils [8–11], as
a result of fragmentation of mature fibrils or large aggregates [12],
or as off-pathway products formed through alternative aggregation
mechanisms [13–15]. Small oligomeric PrP particles produced by
sonication from large pathogenic aggregates of the prion protein
(PrP
Sc) were found to exhibit the highest specific prion infectivity
[16]. Aggregation of mature fibrils into deposits and plaques is
considered to be a protective mechanism that evolved in nature to
avoid the high intrinsic toxicity of soluble oligomers or small
fibrillar fragments [3,5,17]. Defining the relationship between size,
molecular architecture and toxicity of protein aggregates is
essential for developing effective strategies for therapeutic
intervention against neurodegenerative diseases.
Thecurrentstudies weredesigned totest the hypothesis about the
relationship between prion protein fibril dimension and their
cytotoxic potential and specifically, to address the question of
whether fragmentation of fibrils into smaller fragments or oligomers
always enhances toxic potential. To address this question, two
conformationally different fibrillar amyloid states referred to as R-
and S-fibrils were produced from highly-pure, full-length Syrian
hamster rPrP. The cytotoxic potential of intact fibrils and small
fibrillar fragments generated by sonication was tested using cultured
cells. For one amyloid state, fibril fragmentation was found to
enhance its cytotoxic potential, whereas for another amyloid state
formed within the same amino acid sequence, the fragmented fibrils
were found to be less toxic than the intact fibrils. These studies show
that molecular structure of the amyloid state controls the
relationship between fibrillar size and toxicity.
Results
The R- and S-fibrils were formed from full-length rPrP
encompassing residues 23–231 under identical solvent conditions
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20244but different agitation modes as previously described [18]. To
examine the relationship between physical size and cytotoxicity,
R- and S-fibrils were fragmented using a well-controlled sonication
procedure (Fig. 1) [12], and toxicities of intact and fragmented
fibrils were tested using cultured cells. Importantly, after
sonication, R- and S-amyloid states preserved their individual S-
or R-specific conformations despite smaller particle size [19].
In our previous study, the cells of non-neuronal origin were
found to exhibit the same ranking order in their susceptibility with
respect to the toxic effect of different rPrP isoforms as cells of
neuronal origin [20]. Because the toxic effects of extracellular PrP
aggregates is known to be mediated by a surface-expressed PrP
C
[20–24], in choosing the cell lines for the current study we were
guided by the range of PrP
C expression but not by the cell type.
We chose two SKMEL cell lines, SKMEL-2 and SKMEL-28 that
express PrP
C at very low or high levels, respectively (Fig. 2). For
the same reasons, Chinese Hamster Ovary (CHO) cells were used
in parallel with CHO cells transfected with pcDNA5/FRT/PrP
plasmid containing the gene for expression of wild type full-length
Syrian hamster PrP
C (Fig. 2). Two assays were used for evaluating
the effect of intact or fragmented R- or S-fibrils on cultured cells.
The XTT assay assesses cell metabolism by measuring the activity
of mitochondrial dehydrogenases, whereas trypan blue selectively
stains dead cells.
Comparative analysis of cell viability within each cell line and
between lines revealed the following relationships (Fig. 3). First, the
cell lines that expressed low levels of PrP
C (SKMEL-2 and non-
transfected CHO cells) showed very modest cytotoxic responses.
The toxic effects tend to be higher in the lines with high levels of
PrP
C expression (SKMEL-28 and transfected CHO cells)
(Fig. 3A,B). Second, contrary to the prevailing view, fragmented
R-fibrils were found to be substantially less toxic than the intact R-
fibrils in all cultured cells (Fig. 3A,B). In fact, as judged from both
assays, fragmented R-fibrils had minimal effect, if any, as
compared to the non-treated controls. Again, when treated with
intact R-fibrils, the cellular response was weaker in lines with low
levels of PrP
C expression. Third, the cytotoxic potential of S-fibrils
followed the opposite trend (Fig. 3A,B): the toxicity of fragmented
S-fibrils were similar or more pronounced as compared to intact S-
fibrils. These findings revealed that small fibrillar fragments were
more toxic than the intact fibrils for one amyloid structure,
whereas for the alternative amyloid structure the small fragments
were considerably less toxic than the intact fibrils. Interestingly,
while fragmented R-fibrils were much smaller than the intact S-
fibrils (Fig. 1), the former were generally less toxic than the latter
(Fig. 3). This observation further supports the notion that size
difference alone can not explain the toxic potential of amyloid
states.
The differences in amplitude of response between the two assays
were probably due to the fact that the XTT assay probes changes
in the cell metabolism that could be considered as an intermediate
step in a cell’s response, whereas trypan blue assesses the
percentage of cells that were irreversibly damaged and died.
Regardless of the level of PrP
C expression, all cell lines showed
similar rank orders with respect to their susceptibilities to intact or
sonicated R- or S-fibrils within each individual cell line (Fig. 3A,B).
Figure 1. Atomic Force Microscopy imaging of R- and S-fibrils. Phase AFM images of intact R- and S-fibrils (A and B, respectively), or R- and S-
fibrils after fragmentation by ultrasound treatment (C and D respectively). Scale bars=0.5 mm.
doi:10.1371/journal.pone.0020244.g001
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CHO+PrPC or SKMEL-2 and SKMEL-28 were relatively minor,
which could be due to the fact that both SKMEL-2 and CHO
express low levels of PrP
C (PrP
C in CHO can be detected using
polyclonal serum R073 [25]), To test the extent to which the toxic
effects of intact R- or fragmented S-fibrils were mediated by PrP
C,
SKMEL-28 cells were transduced with lentiviruses carrying
shRNAs that were designed to silence Prnp, the gene encoding
PrP
C expression, via RNA interference. Two lentiviruses were
constructed using shRNA-PrP
C vectors corresponding to two
different segments within the 39 UTR region of the human Prnp
gene (will be referred to as shRNA-PrP
C#1 and shRNA-PrP
C#2).
As judged from Western blotting, expression of PrP
C was silenced
in cells treated with shRNA-PrP
C#1 lentivirus, but not in cells
transduced with shRNA-PrP
C#2 or with scrambled shRNA
lentiviruses (Fig. 4A). These differences could be attributed to
the differences in sequences of shRNA-PrP
C#1 and shRNA-
PrP
C#2 or differences in sites of chromosomal integration of two
lentiviruses. To assess the role of PrP
C, SKMEL-28 cells were
transduced by shRNA-PrP
C#1 or scrambled shRNA lentiviruses
and then treated with intact or fragmented R- or S-fibrils (Fig. 4B).
Consistent with previous data, non-transduced cells or cells
transduced by scrambled shRNA lentivirus showed substantial
reduction in mitochondrial activity after treatment with intact R-
fibrils or fragmented S-fibrils (Fig. 4B). Cells treated with
fragmented R- or intact S-fibrils exhibited very modest reduction
in dehydrogenase activity in comparison to non-treated controls
(Fig. 4B). Transduction of cells with shRNA-PrP
C#1 lentivirus
substantially reduced the deleterious effect of intact R-fibrils and
partially diminished the effect of fragmented S-fibrils (Fig. 4B).
However, silencing of PrP
C expression by shRNA-PrP
C#1 had no
measurable effects on cells treated with fragmented R- or intact S-
fibrils, which both exhibited minor cytotoxic effects (Fig. 4B).
These data supported the previous results obtained with cell lines
that express PrP
C at different levels and revealed that the toxic
effects of both R- and S-structures were mediated at least in part
by PrP
C. Considering that the mitochondrial activity in cells
treated with shRNA-PrP
C#1 lentivirus was not restored fully,
there might be an alternative, PrP
C-independent mechanism that
mediates toxic signals of extracellular PrP aggregates.
Discussion
Establishing the relationship between the physical state of a
protein and toxicity is essential for developing effective therapeutic
strategies against neurodegenerative diseases. In the prevailing
opinion, soluble oligomers or small fibrillar fragments are
considered to be the most toxic species, whereas formation of large
amyloid fibrils and plaques are thought to be a protective process by
which cells sequester more dangerous oligomers [3–7]. The present
finding provides new opportunities for reexamining this view. This
work warns that without specifying the molecular structures of the
protein aggregates, claims regarding the relationships between size
and toxicity of amyloid states could be misleading.
The current study revealed that for the S-structures produced
from full-length recombinant prion protein, small fibrillar
fragments were more toxic than the intact fibrils, whereas for
the R-structures produced from the same protein, the small
fragments were considerably less toxic than the intact fibrils.
Remarkably, fragmentation of R-fibrils almost completely abol-
ished their cytotoxic potential. Considering that both R- and S-
fibrils are produced within the same amino acid sequence using
highly pure rPrP [18,19], the differences in cell response to intact
versus fragmented fibrils have to be attributed to the distinct
molecular structures of the two amyloid states. The R- and S-
structures were analyzed previously using a broad range of
biophysical techniques including X-ray diffraction, CD, hydrogen-
deuterium exchange Raman spectroscopy, FTIR spectroscopy,
hydrogen-deuterium exchange monitored by FTIR, proteinase K
(PK)-digestion assay, binding of a conformation-sensitive fluores-
cence dye, immunoconformational assay, atomic force microscopy
and electron microscopy [18,19]. The R- and S-fibrils were found
to have fundamentally different secondary, tertiary and quaternary
structures [19]. While both amyloid states displayed a 4.8 A ˚
meridional X-ray diffraction typical for amyloid cross-b spines,
they showed markedly different equatorial profiles suggesting
fundamentally different architectures of the cross b-spine [19].
Using solid state NMR, the cross-b core of R-fibrils was found to
consist of in-register, parallel b-sheet structure [26]. No molecular
details are currently available from NMR methods about structure
of S-fibrils. Nevertheless, together with previous studies this work
demonstrates that the relationship between fibril size and their
cytotoxic potential is not unidirectional and is controlled by the
molecular structures of the amyloid states.
The current work demonstrated the remarkable ability of cells
to recognize and respond differently to conformationally distinct
amyloid states even if they are formed within the same amino acid
sequence. As evident from previous studies, not only were the cross
b-spine structures markedly different in R- and S-fibrils, but also
their surface epitope presentation and PK-resistant regions
[18,19]. For instance, the epitope to R1 antibodies (resides 225–
231) was found to be solvent exposed in S-fibrils, but buried in the
fibrillar interior in R-structures [18]. The N-terminal region 23–
,50 was found to be PK-resistant in S-structures, but PK-sensitive
in R-fibrils [19]. As judged from the epitope presentation and PK-
resistant profile, R-fibrils resembled the structure of PrP
Sc more
closely than the S-fibrils. Moreover, unlike S-fibrils, R-fibrils were
found to be capable of inducing a transmissible form of prion
diseases in wild type animals [27]. Unexpectedly, fragmentation of
R-amyloids into fibrils of shorter length was found to abolish their
cytotoxic potential, an observation that contradicts the currently
dominating view. We do not know whether the cellular response is
controlled by R- or S-specific differences in their cross b-spines or
by differences in the presentation of epitopes on lateral fibrillar
surfaces.
Figure 2. Analysis of PrP
C expression in CHO and SKMEL cell
lines. CHO cells before transfection (CHO) or after transfection with
pcDNA5/FRT/PrP plasmid (CHO+PrP
C), and SKMEL-2 or SKMEL-28 cells
(10
7 cells for each cell line) were lysed and analyzed by Western blotting
using mouse anti-PrP 3F4 or mouse anti-b-actin antibody. NBH – 10%
normal hamster brain homogenate. b-actin was used as a loading
control.
doi:10.1371/journal.pone.0020244.g002
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neuronal and non-neuronal origin in a variety of tissues [28–32].
As in the case for PrP
Sc-induced toxicity [21–24], the toxic
potential of the R- and S-amyloid structures was found to depend
in part on the level of PrP
C expression. A growing number of
studies illustrate that on cell surface PrP
C interacts with and
Figure 3. Analysis of cytotoxic potential of intact or fragmented R- and S-fibrils. Percentage of cell death (A) or activity of mitochondrial
dehydrogenases (B) in CHO cells, CHO cells transfected with pcDNA5/FRT/PrP plasmid (CHO+PrP
C), SKMEL-2, and SKMEL-28 cells as measured by
Trypan Blue (A) or XTT (B) assays, respectively. Cells were seeded at 10
6cells/cm
2 density, cultured for one day prior to administration of rPrP fibrils
(1 mM), and then for 24 hours after administration of intact (I) or fragmented (F) R- or S-fibrils. Contr – untreated controls. Each data set represents a
mean value 6 SD of three independent experiments for both assays. Approximately 500 cells were counted for each data point in each experiment
for the Trypan Blue assay. In the XTT assay, XTT activities of untreated controls were set at 100% in each independent experiment. Statistical analyses
were performed using Student’s t-test. *P,0.05; **P,0.005; ***P,0.0005; NS, non-significant.
doi:10.1371/journal.pone.0020244.g003
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fibrils formed by non-PrP proteins or peptides [33–35]. These
findings suggest that PrP
C might be involved in mediating toxic
signals in a number of neurodegenerative diseases. The results of
the current studies support the idea that silencing of PrP
C
expression offers a valuable therapeutic strategy as it limits the
toxic effects of large fibrils or small fibrillar fragments. PrP
C
dependence of the cellular response does not exclude the
possibility that different signaling cascades are triggered by
structurally different fibrils or particles, and that fibril-triggered
toxicity might involve multiple mechanisms [36]. Sporadic
Creutzfeldt-Jakob Disease is known to display substantial hetero-
geneity in neuropathological features including variations in lesion
profile and PrP
Sc deposition [37,38]. It would be difficult to
explain the substantial phenotypic variations in pathology
observed within the same class of neurodegenerative maladies, if
one ignores conformational diversity of aggregated states and the
possibility that each of these states exhibit the capacity of
recruiting a variety of cytotoxic mechanisms. Nevertheless,
extrapolating the relationships between molecular structure, size
and cytotoxicity observed in cultured cells to the pathology in vivo
needs to be considered with great caution because glial cells and
astrocytes might neutralize aggregates of a certain size, protecting
neuronal cells, or become activated and inflamed leading to
additional neuronal damage [39–41]. Considering that silencing of
PrP
C expression by shRNA did not restore cell viability completely
(Fig. 4B), extracellular PrP fibrils might also trigger PrP
C-
independent cytotoxic effects. This result is consistent with
previous findings where extracellular PrP fibrils or oligomers were
shown to exhibit toxicity in a PrP
C-independent manner in
primary neurons or animals [7]. Because PrP
C silencing abolished
the toxic effect of R- and S-structures to a different extent, the role
of PrP
C-mediated versus PrP
C -independent signaling pathways
appears to depend on the structure of toxic aggregates.
While the relationship between fibrillar size and their
pathogenic activity were opposite for R- and S-structures, both
amyloid structures were found to reduce mitochondrial activity
significantly (Fig. 3B). In the last several years, a growing body of
evidence has emerged suggesting that protein deposits, including
aggregates of Ab and PrP, cause mitochondrial dysfunctions
including inhibition or modification of the mitochondrial respira-
tory complex and deleterious alterations in mitochondrial
morphology [33,42–44]. During progression of prion diseases,
functional abnormalities in mitochondria were observed in brain
areas with substantial synaptic pathology, which is considered to
be a key early sign in prion diseases, suggesting that a link exists
between the two abnormalities [42,45]. Previous studies revealed
that treatment of primary neuronal cultures with rPrP or Ab fibrils
caused axonal degeneration and formation of beads composed of
aggregated cytoskeletal and motor proteins as a result of an
impairment of the neuronal transport system [39,43]. Further-
more, in rodent models of the prion diseases, severe axonal
transport defects were found to accompany the progression of the
diseases [46,47].
In summary, this work revealed a deficiency in the current
concept about the relationship between the physical dimension
and cytotoxic potential of ordered protein aggregates. This study
demonstrates that the molecular structure controls the direction in
which the cytotoxic potential of ordered protein aggregates
changes with the change in their physical dimension. This work
helps to find a common ground for conflicting data on size and
toxicity of protein aggregates.
Materials and Methods
Preparation of rPrP fibrils
Syrian hamster full-length rPrP (residues 23–231) was expressed
and purified as previously described [48]. The fibrillation reactions
were conducted in 2 M GdnHCl, 50 mM MES, pH 6.0 at 37uCa t
slow agitation (,60 rpm) and rPrP concentration of 0.25 mg/ml
Figure 4. Effect of PrP
C silencing by shRNA-PrP
C on toxicity of
the R- and S-fibrils. (A) Expression of PrP
C in SKMEL-28 cells (WT) and
SKMEL-28 cells transfected with lentiviruses encoding shRNA-PrP
C#1,
shRNA-PrP
C#2, or scrambled shRNA, or with empty lentiviral vector
(Mock). b-actin was used as a loading control. (B) XTT assay of SKMEL-28
cells transduced with lentiviruses encoding shRNA-PrP
C#1 or scram-
bled shRNA and treated with intact (I) or fragmented (F) R- or S-fibrils
(1 mM). Each data set represents a mean value 6 SD of three
independent experiments. In the XTT assay, XTT activities of untreated
controls were set at 100% in each independent experiment. Activities
for each set of SKMEL-28 cells (non-transfected, transfected with
scrambled shRNA or shRNA-PrPC#1 lentiviruses) were normalized
relative to the corresponding controls. Statistical analysis was per-
formed using Student’s t-test. *P,0.05; **P,0.01; ***P,0.0005; NS,
non-significant.
doi:10.1371/journal.pone.0020244.g004
Relationship between Fibril Size and Toxicity
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20244for producing R-fibrils or at rapid shaking (,1000 rpm) and rPrP
concentration of 0.5 mg/ml for producing S-fibrils. The yield of
conversion to fibrillar forms was estimated by SDS-PAGE as
previously described [49] and was found to be .99%. For each
preparation, the R- or S-specific fibrillar features were confirmed by
AFM and FTIR as described [18,19]. To prepare fibrillar
fragments, fibrils were subjected to ultrasound treatment for
1 min in a bath sonicator (Bransonic-2510, Danbury, CT) as
previously described [12]. R- or S-fibrillar fragments were
structurally different from the previously described soluble b-
oligomericrPrP particles,whichareformed atacidicpHthroughan
aggregation pathway different from fibrillation [14].
Transfection of CHO cells and analysis of PrP
C expression
FLP-In
TM CHO cells (Invitrogen, Carlsbad, CA) cells were
transfected with pcDNA5/FRT/PrP plasmid (Invitrogen, Carls-
bad, CA) containing the gene for expression of full-length wild
type Syrian hamster PrP
C. pcDNA5/FRT/PrP plasmid was
constructed and used for transfection as previously described
[50]. Consistent with previous studies [25,50], expression of
endogenous PrP
C in non-transfected CHO cells was found to be
below detectible levels, whereas the CHO cells transfected with
pcDNA5/FRT/PrP plasmid expressed PrP
C in amounts compa-
rable to those found in normal hamster brains (Fig. 2). FLP-In
TM
CHO cells before and after transfection and SKMEL-2 (American
Type Culture Collection, Manassas, VA) and SKMEL-28 cells
(American Type Culture Collection ) (10
7 cells for each cell line)
were lysed in ProteoJET Mammalian Cell Lysis Reagent
(Fermantas, Glen Burnie, MD) with a protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN). After centrifugation at
16,0006g for 15 min at 4uC, the supernatant was transferred to a
new tube and protein concentrations were determined by
absorbance spectroscopy. Twelve micrograms of total protein
were loaded to 12% SDS-PAGE, and then analyzed by Western
blotting using mouse anti-PrP 3F4 or mouse anti-b-actin
antibodies (Sigma-Aldrich, Saint Louis, MO).
Cytotoxicity Assays
The cytotoxic potential of rPrP fibrils was assessed using
Chinese hamster ovary cell (CHO) or human melanoma SKMEL
cell lines. CHO or SKMEL lines were cultured in F-12 medium
(Invitrogen, Carlsbad, CA) or RPMI 1640 (Invitrogen), respec-
tively, both supplemented with 10% fetal bovine serum (Invitro-
gen) in a humidified atmosphere of 5% CO2, 95% air at 37uC.
Intact or fragmented fibrils were added to the cultured cells at
concentrations equivalent to 1 mM (as calculated per concentra-
tion of rPrP molecules) and incubated for 24 h. The cytotoxic
effect was analyzed using Trypan Blue (Mediatech, Manassas, VA)
or XTT (Sigma-Aldrich, Saint Louis, MO) assays according to the
manufacturer’s procedure. Briefly, for the Tryptan Blue assay,
after treatment with fibrils, cells were trypsinized, incubated with
0.2% trypan blue solution (Mediatech, Manassas, VA) for
2 minutes, and counted using light microscopy. For the XTT
assay, XTT (2,3-Bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetra-
zolium-5-carboxanilide) was added to the amount equal to 20% of
the culture medium volume, the cells were then incubated for four
hours in 5% CO2 at 37uC, and the dehydrogenase activity was
measured by monitoring absorbance at 450 and 690 nm
according to the manufacturer’s procedure.
Construction of lentiviral-derived vectors carrying shRNA-
PrP
C
Target sequences were derived from the 39 UTR region of
human Prnp gene (GenBank BC022532). CAATAGGGAGA-
CAATCTAA (1899-1917, sequence #1) and GCAATGTTAT-
TATTGGCTT (2054–2072, sequence #2) were selected as target
sequences for silencing the expression of PrP
C, the scrambled
sequence GAATGCAATAACGAGAGTA was used as a negative
control for testing the effects of non-specific shRNA. To avoid off-
target effects, a homology search was performed using BLAST
(http://blast.ncbi.nlm.nih.gov) to ensure that only the PrP
C
mRNA sequence was targeted. Two complementary oligonucle-
otides necessary to create the hairpin insert for pENTR-H1/TO
vectors were designed using SiRNA Scales software [51]. The
following single stranded oligonucleotides were synthesized:
shRNA-PrP
C#1-Top, 59-CACCGAATAGGGAGACAATCT-
AACGAATTAGATTGTCTCCCTATTC-39
shRNA-PrP
C#1-Bot., 59-AAAAGAATAGGGAGACAATCT-
AATTCGTTAGATTGTCTCCCTATTC-39
shRNA-PrP
C#2-Top, 59-CACCGCAATGTTATTATTGG-
CTTCGAAAAGCCAATAATAACATTGC-39 shRNA-PrP
C#2-
Bot., 59-AAAAGCAATGTTATTATTGGCTTTTCGAAGCC-
AATAATAACATTGC-39 shRNA-Scrmbl-Top, 59-CACCGA-
ATGCAATAACGAGAGTACGAATACTCTCGTTATTGCA-
TTC-39 shRNA-Scrmbl-Bot., 59-AAAAGAATGCAATAACGA-
GAGTATTCGTACTCTCGTTATTGCATTC-39
After annealing, each double-stranded oligonucleotide (5 nM)
was cloned into pENTR/H1/TO vector (Invitrogen, Carlsbad,
CA). To construct shRNA-expression vectors, recombination
reactions of pENTR/H1/TO vectors that included specific target
sequences with pLenti4/BLOCK-iT-DEST vector (Invitrogen,
Carlsbad, CA) were performed. For producing lentivirus, the
resulting pLenti4/BLOCK-iT-DEST vectors were mixed with
ViraPower Packaging Mix (Invitrogen, Calrsbad, CA), transfected
into 293FT cells (6610
6), and virus-containing supernatants were
harvested 72 hours post-transfection. The lentiviruses were added
to the SKMEL-28 cell line at a multiplicity of infection (MOI) of
2–5, and cells were cultured using a complete medium containing
50 mg/ml Zeocin (Invitrogen, Carlsbad, CA) for 14 days to
establish stable cell lines.
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